Samsung Biologics says it is raising about 3 trillion won (roughly $2.2 billion) through a rights offering to finance its planned acquisition of PolyPeptide Group. The company also plans to expand its manufacturing footprint in South Korea as part of the same funding effort.
Korea Times reports that Samsung Biologics will issue 2.27 million new shares, representing about 4.9% of its outstanding shares. The rights offering is priced at 1.322 million won per share, which would raise approximately 3 trillion won in total. The company allocates most of the proceeds—about 2.7 trillion won—for the PolyPeptide deal and sets aside about 294.8 billion won for facility investment tied to its sixth plant in Incheon.
Following the announcement, Korea Times says Samsung Biologics’ share price falls, reflecting dilution concerns from the increased number of outstanding shares. Analysts cited by the outlet also point to longer-term benefits, including the ability to strengthen capacity and position the company to serve growing demand connected to materials used in obesity treatments. Bloomberg focuses on the scale and purpose of the fundraising, while Korea Times adds the detailed terms and immediate market reaction.
